About the Antibody Characterization Program

Many cancer researchers lack access to affordable, well-characterized, and analytically validated renewable affinity reagents, a problem that could be hindering cancer biomarker discovery and validation, cancer diagnostics development, and therapeutics monitoring.

In an effort to accelerate cancer research and provide well-characterized monoclonal antibodies to the scientific community, the National Cancer Institute's (NCI's) Office of Cancer Clinical Proteomics Research launched the Antibody Characterization Program as part of the Clinical Proteomic Technologies for Cancer (CPTC) initiative.

This program aims to provide antibodies and other critical resources to support protein/peptide measurement and analysis efforts, with a current focus on proteins related to human cancer.

How Can the Antibody Characterization Program Help Your Research?

If your lab needs monoclonal antibodies developed for certain cancer targets:

1. You can submit a request for antibodies to the Antibody Characterization Program by July 11. Make sure to have all materials (i.e. target proteins or peptides) ready and available at time of submission.

2. Your request will then be reviewed and considered based on the justification you provide, and whether the requested antibodies will contribute to existing NCI-funded projects and/or have a broad utility. Priority will be given to projects applying antibodies to proteomics research.

3. For any accepted requests, up to three monoclonal antibodies are generated for each protein/peptide target and characterized using standardized assays that include, but are not limited to: isotype, SDS-PAGE, western blot, ELISA, immunohistochemistry, immuno-mass spectroscopy, and surface plasmon resonance.

View full program details and submit a request.

Are the Antibodies You Need Already Available?

You can find out by searching the database of currently available reagents at the CPTC Antibody Portal.